Director of ALTERITY THERAPEUTICS (ATHE) granted 1,000,000 listed options at $1.00

Rhea-AI Filing Summary

ALTERITY THERAPEUTICS LTD director Lawrence Bernard Gozlan, through Montoya Pty Ltd <Buttercup A/C>, received a grant of derivative securities. The award consists of 1,000,000 listed options, each exercisable into one ordinary share at an exercise price of $1.0000 per share.

The options were granted on 15 June 2026 and expire on 15 June 2031. Following this grant, the indirect holdings reported in this listed option position total 1,000,000 options.

Insights

Equity compensation analyst

Director received 1,000,000 long-dated options as equity compensation.

The filing shows 1,000,000 listed options granted to an entity associated with director Lawrence Bernard Gozlan. Each option is exercisable at $1.0000 per share into ordinary shares, expiring on June 15, 2031.

This is a compensation-related acquisition rather than an open-market purchase or sale. The transaction is classified as a grant/award, with indirect ownership reported via Montoya Pty Ltd <Buttercup A/C>. There are no same-day sales or exercises disclosed in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gozlan Lawrence Bernard

Role null

Type	Security	Shares	Price	Value
Grant/Award	Listed option exp 15 Jun 2031	1,000,000	$0.00	--

Holdings After Transaction: Listed option exp 15 Jun 2031 — 1,000,000 shares (Indirect, Montoya Pty Ltd <Buttercup A/C>)

Footnotes (1)

Key Figures

Options granted: 1,000,000 options Exercise price: $1.0000 per share Expiration date: June 15, 2031 +2 more

5 metrics

Options granted 1,000,000 options Listed option grant on June 15, 2026

Exercise price $1.0000 per share Conversion or exercise price for listed options

Expiration date June 15, 2031 Option term end date

Underlying shares 1,000,000 ordinary shares Shares underlying the listed options

Post-grant derivative holdings 1,000,000 options Total listed options following transaction

Key Terms

Listed option, exercise price, expiration date, indirect ownership, +1 more

5 terms

Listed option financial

"security_title: "Listed option exp 15 Jun 2031""

exercise price financial

"conversion_or_exercise_price: "1.0000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2031-06-15T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

indirect ownership financial

"direct_or_indirect: "I", ownership_type: "indirect""

underlying security financial

"underlying_security_title: "Ordinary shares""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 07:38 PM Accepted by SEC EDGAR 06/23/2026 - 07:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gozlan Lawrence Bernard

(Last) (First) (Middle)

LEVEL 15

500 COLLINS STREET

(Street)

MELBOURNE VICTORIA 3000

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Issuer Name and Ticker or Trading Symbol
ALTERITY THERAPEUTICS LTD [ ATHE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol
[ATH.ASX]

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Listed option exp 15 Jun 2031	$1	06/15/2026	06/15/2026	A		1,000,000		06/15/2026	06/15/2031	Ordinary shares	1,000,000	$0	1,000,000	I	Montoya Pty Ltd <Buttercup A/C>

Explanation of Responses:

	Lawrence Bernard Gozlan	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ALTERITY THERAPEUTICS (ATHE) report in this Form 4 filing?

ALTERITY THERAPEUTICS reported a grant of 1,000,000 listed options to an entity associated with director Lawrence Bernard Gozlan. These options were awarded as derivative securities, not bought on the open market, and give rights to acquire ordinary shares at a fixed exercise price.

How many options did the ATHE director-related entity receive and at what exercise price?

An entity associated with ATHE director Lawrence Bernard Gozlan received 1,000,000 listed options. Each option has an exercise price of $1.0000 per share, allowing the holder to acquire ordinary shares at that fixed price if the options are exercised before expiration.

When do the newly granted ATHE listed options expire?

The 1,000,000 listed options granted to the entity linked to director Lawrence Bernard Gozlan expire on June 15, 2031. The grant date and expiration date match the option’s stated term, giving a long-dated window to decide whether to exercise into ordinary shares.

Is this ATHE Form 4 transaction an open-market buy or a compensation grant?

This ATHE Form 4 reflects a compensation-related grant, not an open-market purchase. The transaction code is reported as a grant, award, or other acquisition of derivative securities, providing options to acquire ordinary shares at a $1.0000 exercise price through June 15, 2031.

How is ownership of the ATHE options held for this Form 4 reporting person?

The 1,000,000 listed options are reported as held indirectly through Montoya Pty Ltd <Buttercup A/C>. The filing classifies the holdings as indirect ownership associated with director Lawrence Bernard Gozlan, rather than shares or options held directly in his personal name.